ArticleCureus2026
Lipid and High-Density Lipoprotein (HDL) Subfraction Changes in Premenopausal and Postmenopausal Women With Breast Cancer Receiving Hormonal Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimHormonal modulation therapy is an important component of hormone receptor-positive breast cancer treatment. However, the type and duration of hormonal therapies have distinct effects on lipid profile parameters and cardiovascular disease risk. This study aimed to investigate the impact of tamoxifen and aromatase inhibitors (AIs) on lipid profiles and high-density lipoprotein (HDL) subfractions in women with breast cancer. MATERIALS AND
methodsIn this retrospective observational study, 100 women were included (50 healthy controls and 50 patients with histologically confirmed breast cancer). Among breast cancer patients, 25 were premenopausal receiving tamoxifen treatment, and 25 were postmenopausal receiving AI therapy, based on routine clinical practice. Lipid parameters were assessed at baseline and following six months of treatment in all participants. Premenopausal patients received tamoxifen, while postmenopausal patients were treated with AIs. Serum total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), HDL cholesterol, and HDL subfractions (HDL-2 and HDL-3) were analyzed.
resultsIn the tamoxifen-treated premenopausal cohort, total cholesterol decreased by 8.48% and LDL-C by 15.94%, with redistribution toward larger HDL particles, reflected by an increase in HDL-2 of 21.1% and a decrease in HDL-3 of 12.06% (all p<0.001). In the postmenopausal aromatase inhibitor cohort, a mixed lipid pattern was observed, with increases in total cholesterol (+3.38%) and LDL-C (+7.02%), decreases in HDL-C (-1.56%) and HDL-2 (-20.75%), an increase in HDL-3 (+8.69%), and a decrease in triglycerides (-10.95%) (all p<0.001). Direct comparison of change scores between cohorts showed significant differences for all examined lipid parameters (all p<0.001).
conclusionDistinct six-month trajectories in lipid profile parameters and HDL subfractions were observed between premenopausal women receiving tamoxifen and postmenopausal women receiving aromatase inhibitors. These findings likely reflect the combined influence of endocrine therapy and underlying menopausal physiology and should not be interpreted as a direct causal head-to-head comparison of isolated drug effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.